ER-Positive Breast Cancer
Equivalent response rate for women with ERBB2-positive metastatic breast cancer receiving taxanes
SERMs and aromatase inhibitors have been proven to be excellent agents in the preventive setting for ER-positive breast cancer, but newer agents must be found specifically for ER-negative breast cancers, which mostly occur in premenopausal women.
The antimalarial drug hydroxychloroquine (HCQ) reverses resistance to tamoxifen in mice, according to investigators.
An inexpensive malaria drug could be the answer for some women who are not responding to their cancer treatment, according to a promising but preliminary animal study.
In estrogen receptor (ER)+ breast cancer, obesity is positively associated with breast cancer mortality only among pre-/peri-menopausal women, according to new research.
Younger women who smoke appear to be at increased risk for developing ER-positive breast cancer, according to research, but no association found for risk of triple-negative breast cancer.
Human breast tumors transplanted into mice are excellent models of metastatic cancer and are providing insights into how to attack breast cancers that no longer respond to the drugs used to treat them, according to research presented at the 2013 San Antonio Breast Cancer Symposium.
A phase 1 trial of endoxifen, an active metabolite of the cancer drug tamoxifen, indicates that the experimental drug is safe and provides early evidence for antitumor activity.
As cholesterol is metabolized, a potent stimulant of breast cancer is created—one that fuels estrogen receptor (ER)-positive breast cancers, according to new research.
A type of mutation that develops after breast cancer patients take antiestrogen therapies has been identified. These mutations help to explain why patients often become resistant to these types of therapies.
The breast cancer index (BCI) was the only one of three methods compared that predicted the risk for recurrence in women treated for estrogen-receptor (ER)-positive breast cancer.
A specific change that occurs when breast cancer tumors become resistant to antiestrogen therapy might make the tumors susceptible to treatment with chemotherapy drugs.
Researchers have identified the signaling pathway that is overactivated in estrogen receptor (ER)-positive breast cancer cells that are resistant to hormone therapies such as tamoxifen, aromatase inhibitors, or fulvestrant.
Sign Up for Free e-newsletters
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Identifying the Psychosocial Needs of Young Adults With Metastatic Cancer
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- When There Are No Words: Interpreting Patients' and Families' Subtle Messages
- Depression Predictive of Poor Survival Outcomes in Head and Neck Cancer
- Nearly One Third of Veterans Report Current Tobacco Use
- Priority Review of New Drug Application Granted to Apalutamide for CRPC
- Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|